All News

2020

September

Media Release / Sep 11, 2020

Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)

Read More
Media Release / Sep 11, 2020

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

Read More
Media Release / Sep 08, 2020

Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum

Read More

August

Media Release / Aug 20, 2020

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Read More
Media Release / Aug 17, 2020

Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent

Read More
Media Release / Aug 05, 2020

Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

Read More

July

Adeno-associated viruses
Story / Jul 30, 2020

Collaborating to explore new gene regulation therapies

Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.

Read More

June

Media Release / Jun 29, 2020

Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options

Read More
Media Release / Jun 25, 2020

Novartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis

Read More
Media Release / Jun 02, 2020

Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More